Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Tandon, Manish ^a   Chen, Zujian ^a   Pratap, Jitesh ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B; RICTOR PROTEIN; SERINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; NUCLEAR PROTEIN; PHLPP1 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; RUNX2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST METASTASIS; CANCER CELL; CELL INVASION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDIATOR; PHENOTYPE; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; CORE BINDING FACTOR ALPHA 1 SUBUNIT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MCF-7 CELLS; MORPHOLINES; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES;

EID: 84893207197     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3611     Document Type: Article

References (60)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562. 10.1038/nrc2664, 19629070.
3. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009, 8:1-9. 2775557, 19139107.
4. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764. 10.1016/S0092-8674(00)80258-5, 9182763.
5. Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, Lian JB, Stein GS. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 2009, 69:6807-6814. 10.1158/0008-5472.CAN-09-1471, 2742766, 19690135.
6. Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, Sasano H. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 2010, 101:2670-2675. 10.1111/j.1349-7006.2010.01742.x, 20946121.
7. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003, 56:13-22. 10.1002/pros.10233, 12746842.
8. Li H, Zhou RJ, Zhang GQ, Xu JP. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumour Biol 2013, 34:1807-1812. 10.1007/s13277-013-0720-4, 23471668.
9. Li W, Xu S, Lin S, Zhao W. Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. J Biomed Biotechnol 2012, 2012:456534. 3475129, 23093845.
10. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA. The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011, 2011:282745. 3005824, 21197465.
11. Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C, Soong R, Pho RW, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 2009, 36:153-158. 10.1007/s11033-008-9378-1, 2981062, 18931939.
12. Pratap J, Lian JB, Stein GS. Metastatic bone disease: role of transcription factors and future targets. Bone 2011, 48:30-36. 10.1016/j.bone.2010.05.035, 2958222, 20561908.
13. Westendorf JJ. Transcriptional co-repressors of Runx2. J Cell Biochem 2006, 98:54-64. 10.1002/jcb.20805, 16440320.
14. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 2011, 13:R127. 10.1186/bcr3073, 3326569, 22151997.
15. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, van Wijnen AJ, Young MF, Lian JB, Stein GS, Gerstenfeld LC. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003, 63:2631-2637.
16. Chimge NO, Frenkel B. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 2013, 32:2121-2130. 10.1038/onc.2012.328, 23045283.
17. Mendoza-Villanueva D, Deng W, Lopez-Camacho C, Shore P. The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells. Mol Cancer 2010, 9:171. 10.1186/1476-4598-9-171, 2905338, 20591170.
18. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005, 25:8581-8591. 10.1128/MCB.25.19.8581-8591.2005, 1265732, 16166639.
19. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006, 25:589-600.
20. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008, 68:7795-7802. 10.1158/0008-5472.CAN-08-1078, 2596479, 18829534.
21. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502. 10.1016/j.devcel.2007.03.020, 17419990.
22. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22. 10.1016/j.ccr.2007.05.008, 17613433.
23. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011, 1813:1978-1986. 10.1016/j.bbamcr.2011.03.010, 21440011.
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
25. Li LB, Toan SV, Zelenaia O, Watson DJ, Wolfe JH, Rothstein JD, Robinson MB. Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype. J Neurochem 2006, 97:759-771. 10.1111/j.1471-4159.2006.03743.x, 16573655.
26. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 2003, 63:5357-5362.
27. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101. 10.1126/science.1106148, 15718470.
28. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003, 77:8957-8961. 10.1128/JVI.77.16.8957-8951.2003, 167245, 12885912.
29. Tandon M, Gokul K, Ali SA, Chen Z, Lian J, Stein GS, Pratap J. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. Mol Cancer 2012, 11:27. 10.1186/1476-4598-11-27, 3377538, 22537242.
30. Wingender E, Kel AE, Kel OV, Karas H, Heinemeyer T, Dietze P, Knuppel R, Romaschenko AG, Kolchanov NA. TRANSFAC, TRRD and COMPEL: towards a federated database system on transcriptional regulation. Nucleic Acids Res 1997, 25:265-268. 10.1093/nar/25.1.265, 146363, 9016550.
31. Shen H, Maki CG. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4 N cells. J Biol Chem 2010, 285:23105-23114. 10.1074/jbc.M110.124990, 2906304, 20489208.
32. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899. 10.1158/0008-5472.CAN-03-2904, 15172999.
33. Huang H, Tindall DJ. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 2011, 1813:1961-1964. 10.1016/j.bbamcr.2011.01.007, 3110514, 21238503.
34. Liu Q, White LR, Clark SA, Heffner DJ, Winston BW, Tibbles LA, Muruve DA. Akt/protein kinase B activation by adenovirus vectors contributes to NFkappaB-dependent CXCL10 expression. J Virol 2005, 79:14507-14515. 10.1128/JVI.79.23.14507-14515.2005, 1287576, 16282450.
35. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006, 7:85-96. 10.1038/nrm1837, 16493415.
36. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005, 18:13-24. 10.1016/j.molcel.2005.03.008, 15808505.
37. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, Fesik S, Ram PT, Mills GB. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011, 30:4567-4577. 10.1038/onc.2011.164, 3175328, 21666717.
38. Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 2006, 8:1-8. 10.1593/neo.05373, 1601146, 16533420.
39. Drissi H, Pouliot A, Stein JL, van Wijnen AJ, Stein GS, Lian JB. Identification of novel protein/DNA interactions within the promoter of the bone-related transcription factor Runx2/Cbfa1. J Cell Biochem 2002, 86:403-412. 10.1002/jcb.10238, 12112009.
40. Park OJ, Kim HJ, Woo KM, Baek JH, Ryoo HM. FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization. J Biol Chem 2010, 285:3568-3574. 10.1074/jbc.M109.055053, 2823497, 20007706.
41. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH, Ryoo HM, Choi JY, Yoshida M, Nishino N, Oh BC, Lee KS, Lee YH, Bae SC. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006, 281:16502-16511. 10.1074/jbc.M512494200, 16613856.
42. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K, Komori T. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166:85-95. 10.1083/jcb.200401138, 2172136, 15226309.
43. Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem 2006, 281:7118-7128. 10.1074/jbc.M508162200, 16407259.
44. Rajgopal A, Young DW, Mujeeb KA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells. J Cell Biochem 2007, 100:1509-1517. 10.1002/jcb.21137, 17171635.
45. Kita K, Kimura T, Nakamura N, Yoshikawa H, Nakano T. PI3K/Akt signaling as a key regulatory pathway for chondrocyte terminal differentiation. Genes Cells 2008, 13:839-850. 10.1111/j.1365-2443.2008.01209.x, 18782222.
46. Pande S, Browne G, Padmanabhan S, Zaidi SK, Lian JB, van Wijnen AJ, Stein JL, Stein GS. Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol 2013, 28:1784-1792.
47. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, Stein GS, Lian JB, Jones SN. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 2006, 172:909-921. 10.1083/jcb.200508130, 2063734, 16533949.
48. Pereira BP, Zhou Y, Gupta A, Leong DT, Aung KZ, Ling L, Pho RW, Galindo M, Salto-Tellez M, Stein GS, Cool SM, van Wijnen AJ, Nathan SS. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J Cell Physiol 2009, 221:778-788. 10.1002/jcp.21921, 2768260, 19746444.
49. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001, 98:11598-11603. 10.1073/pnas.181181198, 58775, 11504915.
50. Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis 2013, 4:e610. 10.1038/cddis.2013.127, 3641350, 23618908.
51. Yang S, Xu H, Yu S, Cao H, Fan J, Ge C, Fransceschi RT, Dong HH, Xiao G. Foxo1 mediates insulin-like growth factor 1 (IGF1)/insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts. J Biol Chem 2011, 286:19149-19158. 10.1074/jbc.M110.197905, 3099728, 21471200.
52. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, Westendorf JJ, Cheng L, Huang H. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011, 71:3257-3267. 10.1158/0008-5472.CAN-10-2603, 3108023, 21505104.
53. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, Stein T, Neil J, Cameron ER. Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol Dis 2010, 45:117-123. 10.1016/j.bcmd.2010.05.007, 20580290.
54. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006, 66:6512-6520. 10.1158/0008-5472.CAN-06-0369, 16818622.
55. Debnath J, Walker SJ, Brugge JS. Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol 2003, 163:315-326. 10.1083/jcb.200304159, 2173511, 14568991.
56. Wang L, Brugge JS, Janes KA. Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci U S A 2011, 108:E803-E812. 10.1073/pnas.1103423108, 3189061, 21873240.
57. Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH, Ge Y. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009, 114:2744-2752. 10.1182/blood-2008-09-179812, 2756129, 19638627.
58. Lin FC, Liu YP, Lai CH, Shan YS, Cheng HC, Hsu PI, Lee CH, Lee YC, Wang HY, Wang CH, Cheng JQ, Hsiao M, Lu PJ. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene 2012, 31:4302-4316. 10.1038/onc.2011.596, 22231444.
59. Pierce AD, Anglin IE, Vitolo MI, Mochin MT, Underwood KF, Goldblum SE, Kommineni S, Passaniti A. Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype. J Cell Biochem 2012, 113:282-292. 10.1002/jcb.23354, 3244527, 21913213.
60. D'Souza DR, Salib MM, Bennett J, Mochin-Peters M, Asrani K, Goldblum SE, Renoud KJ, Shapiro P, Passaniti A. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. J Biol Chem 2009, 284:17947-17955. 10.1074/jbc.M109.002378, 2709386, 19383984.